Skip to content
LULULUF04F04F04

Drawing based on the label description. No photo yet.

“40-mg tablets: Yellow colored, round shaped, beveled edge film-coated biconvex tablets, debossed with 'LU' on one side and 'F04' on the other side”

LU F04 pill

Pill with imprint LU F04 is yellow, round, 15 mm and has been identified as Quinapril 40 mg. It is used for high blood pressure, heart failure and a weak heart. It is supplied by Bluepoint Laboratories.

Quinapril 40 mg

Imprint
LU F04
Strength
40 mg
Used for
High blood pressure, heart failure and a weak heart
Color
Yellow
Shape
Round
Size
15 mm
Score
No score line
Form
Tablet
Manufacturer
Bluepoint Laboratories
Drug class
ACE inhibitor (blood pressure and heart medicine)
NDC
68001-186, 68001-186-05, 68180-559, 68180-559-03, 68180-559-09

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Quinapril pills and guides

What is Quinapril used for?

Quinapril is used for high blood pressure, heart failure, a weak heart and kidney disease from diabetes.

Medicine type
ACE inhibitor (blood pressure and heart medicine)
Official uses from the US prescribing label

Hypertension

Quinapril tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets USP.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).

Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.

Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.

Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.

Quinapril tablets USP may be used alone or in combination with thiazide diuretics.

Heart Failure

Quinapril tablets USP is indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics and/or digitalis.

In using quinapril tablets USP, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril tablets USP does not have a similar risk (see WARNINGS).

Angioedema in black patients

Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.

From the FDA-approved label on DailyMed (published Jan 28, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows LU and the other side shows F04.
  • It is yellow, round, 15 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

According to its label, this product is no longer being made or sold.

Ingredients

Active: Quinapril Hydrochloride

Inactive: Ferric Oxide Yellow, Magnesium Carbonate, Polyvinyl Alcohol, Unspecified, Xanthan Gum, Lecithin, Soybean, Microcrystalline Cellulose, Crospovidone (15 Mpa.s At 5%), Povidone, Unspecified, Talc, Magnesium Stearate, Titanium Dioxide

Also distributed by

Lupin Pharmaceuticals, Inc.

Other pills with imprint LU F04

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Quinapril pills